NCT02233712View on ClinicalTrials.gov

Open-label, Dose-finding Study to Determine Antibody Response to G17DT Treatment in Patients With Gastric Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 31, 1999

Primary Completion Date

March 31, 2000

Conditions
Gastric Cancer
Interventions
BIOLOGICAL

G17DT

Sponsors
All Listed Sponsors
lead

Cancer Advances Inc.

INDUSTRY

NCT02233712 - Open-label, Dose-finding Study to Determine Antibody Response to G17DT Treatment in Patients With Gastric Cancer. | Biotech Hunter | Biotech Hunter